#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neonatal alloimmune thrombocytopenia Vascular calcification Plasma cell myeloma Hyperinsulinaemic hypoglycaemia B-cell lymphoma Anal cancer recurrent Post transplant lymphoproliferative disorder Mantle cell lymphoma stage IV Oropharyngeal cancer recurrent Pancreatic carcinoma Spinal muscular atrophy Malignant melanoma Dent's disease Mixed-type liposarcoma Colorectal cancer metastatic More trials…

    Learn about Rare Diseases

    Myxofibrosarcoma – Life with Disease Retinitis pigmentosa Niemann-Pick disease – Treatment Primary immunodeficiency syndrome – Life with Disease Glomerulonephritis rapidly progressive – Trials in Disease Hepatic angiosarcoma Progressive supranuclear palsy Pemphigus – Basic Information Congenital nephrogenic diabetes insipidus – Treatment Medulloblastoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bi 3032950 Enomimeran Belimumab TAZAROTENE Cocarboxylase Tetrahydrate Mps-200 Lisaftoclax Dornase Alfa Kk8123 Gemcitabine Hydrochloride Birtamimab Censavudine Zolbetuximab Anhydrous Cidofovir Ion440 Dosulepin Hydrochloride Latozinemab VGA039 Aticaprant Temocillin More therapies…

    Learn about Your Condition

    Upper limb fracture Heart transplant Squamous cell carcinoma Glucose tolerance impaired Coronary artery occlusion Malignant oligodendroglioma Gout Glomerulonephritis chronic Strongyloidiasis Head injury Ovarian cancer stage IV Vascular calcification Cardiac arrest Diabetic autonomic neuropathy Impaired gastric emptying More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Muyefa Ztvraqep Kahvr 2ef Dkbycmuyd 4gkyg Htpdymj

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Myelodysplastic syndrome
    Investigated Drugs:
    • Tamibarotene
    • Azacitidine
    Austria Belgium Czechia France Germany Hungary +3

  • Study of Pirtobrutinib, Venetoclax and Rituximab combination compared to Venetoclax and Rituximab in previously treated Chronic Lymphocytic Leukemia patients

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Pirtobrutinib
    • Rituximab
    • Venetoclax
    Belgium Czechia Denmark France Germany Hungary +5

  • Study on the Effects of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis Who Cannot Tolerate Ursodeoxycholic Acid

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Bezafibrate
    • Obeticholic Acid
    Belgium Croatia Czechia Estonia France Germany +6

  • Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Zamtocabtagene Autoleucel
    • Allopurinol
    • Bromhexine Hydrochloride
    Croatia Hungary

  • Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Tofacitinib Citrate
    • Tofacitinib
    Belgium Finland France Germany Hungary Italy +4

  • Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Atorvastatin
    • Inclisiran
    • Rosuvastatin
    Austria Belgium Bulgaria Croatia Czechia Denmark +18

  • Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Czechia Denmark Estonia France +11

  • Study on Extended Access to Momelotinib for Patients with Myelofibrosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Myelofibrosis
    Investigated Drugs:
    • Momelotinib Dihydrochloride Monohydrate
    Belgium Bulgaria Denmark France Germany Hungary +4

  • Study Comparing Risankizumab and Deucravacitinib for Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Deucravacitinib
    • Risankizumab
    Belgium Germany Greece Hungary Italy The Netherlands +1

  • Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Idelalisib
    • Pirtobrutinib
    Austria Belgium Croatia Czechia France Germany +5
Previous Page
1 … 38 39 40 41 42 … 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!